Quality of Life Assessment

Slides:



Advertisements
Similar presentations
Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
Advertisements

College of Occupational Therapists Annual Conference Glasgow 2003.
Trauma Informed Services The Evolution of a Concept
Michelle O’Reilly. Quantitative research is outcomes driven Qualitative research is process driven Please offer up your definitions.
Fabrice Barlési Thoracic Oncology Pôle Cardiovasculaire et Thoracique & EA3279 Marseille - France ERS live lecture – May 21, 2008 Quality of Life in Lung.
1 Epoetin Alpha: FDA Overview of Patient Reported Outcome (PRO) Claims Ann Marie Trentacosti, M.D. Study Endpoints and Labeling Office of New Drugs Food.
EVIDENCE BASED MEDICINE for Beginners
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Family Quality of Life and Application Among People with Intellectual Disabilities and Their Families Professor Robert L. Schalock, Ph.D. Institute of.
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
QUALITY OF LIFE ASSESSMENT IN PEOPLE LIVING WITH HIV/AIDS Antonieta Medina Lara HIV/AIDS and STI Knowledge Programme Liverpool School of Tropical Medicine.
Quality of Life Assessment in Clinical Trials Elizabeth Garrett-Mayer Some slides adapted from qol.pdf.
Quality of Life Assessment in Clinical Trials Adapted from Introduction to Clinical Trials Biostatistics.
Therapeutic Education: Cancer Patients on chemotherapy: Shamim Akhter QURESHI MBBS,MPH, Ingénieur d’étude(EHESP) 2 nd June 2012 June 2010.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
#1 STATISTICS 542 Intro to Clinical Trials Quality of Life Assessment.
Introduction: Medical Psychology and Border Areas
Dr K N Prasad Community Medicine
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
Outcome research 1 Outcome/ instruments selection Wei-Chu Chie Preventive Medicine.
Comprehensive Geriatric Assessment and the Patient- Centered Clinical Method.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Page 1INGID Meeting Budapest, 6 October 2006 Prognostic Factors for Improved Health-Related Quality of Life in Children and Adults With Primary Antibody.
PERSONAL WELLNESS: Taking Charge of Your Health and Well-being.
Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,
Principles of Assessment and Outcome Measurement for Physical Therapists ksu. edu. sa Dr. taher _ yahoo. com Mohammed TA, Omar,
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Surrogate Endpoints as Measures of Efficacy: Complexities & Limitations FDA Advisory Committee November 18, 2002 Michael D. Hughes, Ph.D. Professor of.
Interventions to Improve Physical Activity and Fatigue for Older Patients Receiving Cancer Treatment Karen M. Mustian, Ph.D., M.P.H. Director and Associate.
National Cancer Survivorship Initiative Central Hall, Westminster Monday 21 September 2009 Self Management.
CoRPS London 26 & 27 October 2010 Center of Research on Psychology in Somatic diseases Understanding PRO in hematological disorders: Do we have a consensus?
Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.
Comorbidity and Multimorbidity: Measurement and Interventions Holly M. Holmes, MD, MS Dept of General Internal Medicine.
Got outcome measures? What Clinicians & Investigators Want Lisa M. Shulman, M.D. The Eugenia Brin Professor in Parkinson’s Disease and Movement Disorders.
+ Interdisciplinary Care in Pediatric Chronic Pain Emily Law, PhD Assistant Professor Department of Anesthesiology & Pain Medicine University of Washington.
Some epidemiological principles and methods
Palliative Care: Emergency Room Interaction
Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS
Opioids for the management chronic non-cancer pain in Primary Care:
Survival Analysis Rick Chappell, Ph.D. Professor,
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.
Measurement Wu Gong, MS, MD
Introduction to Clinical Pharmacy
Quality Of Life, Enjoyment And Satisfaction Among Clients Attending Day Care At Psychiatric Rehabilitation Services, NIMHANS, Bangalore: A Pilot Study.
Dialysis Patient’s Satisfaction with their Dialysis Therapy
Chapter Eleven: Management of Chronic Illness
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
The Relationship Between Mental and Physical Health
Cancer Cachexia in GI Malignancies
Rhematoid Rthritis Respiratory disorders
Nursing Process in Pharmacology
Components Mechanisms of action Outcomes
Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.
Mirela Anghelina, M.D., M.P.H.
Physical Activity and Endometrial Cancer Survival
Issues in TB Drug Development: A Regulatory Perspective
SAMHSA’s Wellness Programming
Health Disparities and Case Management
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Regulatory Perspective of the Use of EHRs in RCTs
Measuring outcomes Emma Frew October 2012.
Pulmonary Arterial Hypertension and Hospitalizations
Living with Ovarian Cancer: How Palliative Care Can Help
Classification and Treatment Plans
Statistics for Clinical Trials in Cancer Research
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Quality of Life Assessment Rick Chappell, Ph.D. Professor, Department of Biostatistics and Medical Informatics University of Wisconsin School of Medicine & Public Health chappell@stat.wisc.edu – Week 1, Lecture 1 BMI 542 – Week 8, Lecture 2

Outline for Quality of Life General background Data collection considerations A good reference: Fairclough, Design and Analysis of Quality of Life Studies in Clinical Trials, 2nd ed. Chapman & Hall, 2010.

Why Are We Interested in the Quality of Life? The United States Food and Drug Administration has stated that efficacy with respect to overall survival and/or improvements in QOL might provide the basis for drug approval Shaughnessy JA, Wittes RE, Burke G et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991; 9:2225-32.

What is Quality of Life? WHO: “Health is not only the absence of infirmity and disease, but also a state of physical, mental and social well being Multiple domains: physical, cognitive, emotional and social functioning, pain, sexual functioning, health perceptions, and symptoms such as nausea and fatigue Fundamental principle: quality of life is assessed by the patient

Definition depends on context Cancer vs. MI vs. hypertension Early instruments were disease specific Later, "general health status" instruments POMS = Profile of Mood SIP = Sickness Impact Profile Difficulties with concept No agreement on definitions Lack of standardized measures

One definition (Levine & Croog) Two Components Functioning 1. Social (Major component) - Get along with family & friends | sense of worth 2. Physical - Perform daily life activities 3. Emotional - Stability and self control 4. Intellectual - Decision making ability Perceptions 1. Life Satisfaction - Sense of well being 2. Health Status - Compared to others

Factors Which Influence Quality of Life 1. Intervention 2. Disease Process 3. "Labeling"  Need a control group - Diagnosis brings on change 4. Concomitant Care 5. Non-related life events (e.g. death in family)

Rationale in Clinical Trials Quality of life assesses effect of intervention primary response (treatment less toxic?) side effects (treatment toxic?) economic aspects (low risk/cost treatment but benefit high?)

How To Assess Quality of Life Determine your QOL Objective Choose an instrument Reliable: “A measure is said to have a high reliability if it produces similar results under consistent conditions. “ Valid: “The degree to which an instrument measures what it is supposed to measure.” Global measures, disease-specific measures, symptom checklists Select your assessment time points and administration format Develop an analysis plan

Data Collection Considerations Mode Self-administered glasses, reading skills, fine-motor skills Personal interview training/background of interviewer sensitivity to gender/ethnicity/age hearing impairment

Off-the-Shelf Instruments (Example-Nocturnal O2 Therapy Trial) Design Advanced Chronic Obstructive Pulmonary Disease 24 vs. 12 hours of O2 Quality of life 10 outcome (No norms in this pop!) Quality of Life Results  Patients were sick Patients got worse No treatment difference BUT Mortality ratio was 2/1 (p<.01) Ref: Ann Intern Med. 190, 93, 392-8, no authors listed.